康哲医疗子公司签署变更协议。 China Medical System's subsidiary signed a Novation Agreement.
康哲药业（00867）于2024年2月3日发布公告，其全资子公司与维福尔费森尤斯医疗肾药有限公司、维健投资就羟基氧化蔗糖铁咀嚼片Velphoro®签订了更替协议。 China Medical System (00867) announced on February 3, 2024, that its wholly-owned subsidiary entered into a Novation Agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Investment for the sucroferric oxyhydroxide chewable tablets Velphoro®. 维健投资与VFMCRP于2023年6月28日签署许可协议，授予维健投资在中国大陆、香港、澳门和台湾地区注册、进口、推广、分销、使用和销售该产品的独家许可。 The License Agreement between Winhealth Investment and VFMCRP was signed on June 28, 2023, granting Winhealth Investment an exclusive license to register, import, promote, distribute, use, and sell the product in Mainland China, Hong Kong, Macao, and Taiwan.